Pre-marketing RCTs investigated mostly the comparative therapeutic efficacy and safety of reference product and biosimilar ESAs in the treatment of CKD-related anemia, highlighting no differences in achieving the target Hb value [9–11]. Here, GSTM1 is linked to anemia.